Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -124.67% is 194% below its 5-year average of -42.34%, around the middle of its 5-year range (-211.03%–-28.87%).
As of the fiscal period ended Tuesday, June 30, 2026. 5.50% above its 12-month average of -131.93%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -124.67%.
RETURN ON EQUITY (ROE)
-124.67%
RETURN ON EQUITY (ROE) AVG TTM
-131.93%
RETURN ON EQUITY (ROE) AVG 3Y
-66.32%
RETURN ON EQUITY (ROE) AVG 5Y
-42.34%
RETURN ON EQUITY (ROE) AVG 10Y
-25.89%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+5.50%
CURRENT VS 3Y AVG
-87.99%
CURRENT VS 5Y AVG
-194.44%
CURRENT VS 10Y AVG
-381.63%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.55%
median of 583 covered companies
CURRENT VS SECTOR MEDIAN
-215.22%
vs the sector median at left
AC Immune S.A.
Market Cap
$262.07M
Return on Equity (ROE)
-124.67%
TTM Avg
-131.93%
3Y Avg
-66.32%
5Y Avg
-42.34%
Market Cap
$262.65M
Return on Equity (ROE)
-37.12%
TTM Avg
-62.34%
3Y Avg
-32.67%
5Y Avg
8.91%
Market Cap
$263.09M
Return on Equity (ROE)
-39.55%
TTM Avg
-28.46%
3Y Avg
-79.02%
5Y Avg
-63.95%
Market Cap
$262.11M
Return on Equity (ROE)
-26.24%
TTM Avg
-102.84%
3Y Avg
-107.17%
5Y Avg
-107.44%
Market Cap
$257.22M
Return on Equity (ROE)
-2.76%
TTM Avg
-22.10%
3Y Avg
-22.09%
5Y Avg
-15.95%
Market Cap
$266.79M
Return on Equity (ROE)
-15.46%
TTM Avg
-12.46%
3Y Avg
-4.29%
5Y Avg
-4.49%
Market Cap
$267.84M
Return on Equity (ROE)
-38.33%
TTM Avg
-61.68%
3Y Avg
-393.03%
5Y Avg
-278.88%
Market Cap
$256.22M
Return on Equity (ROE)
-47.25%
TTM Avg
-42.23%
3Y Avg
-50.43%
5Y Avg
-29.25%
Market Cap
$273.56M
Return on Equity (ROE)
-184.27%
TTM Avg
-57.34%
3Y Avg
-61.84%
5Y Avg
-87.31%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AC Immune S.A. (ACIU) | $262.07M | -124.67% | -131.93% | -66.32% | -42.34% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $262.65M | -37.12% | -62.34% | -32.67% | 8.91% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.09M | -39.55% | -28.46% | -79.02% | -63.95% |
| Palisade Bio, Inc. (PALI)vs › | $262.11M | -26.24% | -102.84% | -107.17% | -107.44% |
| Anika Therapeutics, Inc. (ANIK)vs › | $257.22M | -2.76% | -22.10% | -22.09% | -15.95% |
| OraSure Technologies, Inc. (OSUR)vs › | $266.79M | -15.46% | -12.46% | -4.29% | -4.49% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $267.84M | -38.33% | -61.68% | -393.03% | -278.88% |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | -47.25% | -42.23% | -50.43% | -29.25% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $273.56M | -184.27% | -57.34% | -61.84% | -87.31% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $248.50M | -43.11% | -35.75% | -28.47% | -12.53% |
ROE
-124.7%
ROA
-29.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -124.67% |
| 2026-03-31 | -211.03% |
| 2025-12-31 | -152.15% |
| 2025-09-30 | -109.07% |
| 2025-06-30 | -62.74% |
| 2025-03-31 | -53.97% |
| 2024-12-31 | -45.38% |
| 2024-09-30 | -28.87% |
| 2024-06-30 | -48.91% |
| 2024-03-31 | -37.89% |
| 2023-12-31 | -31.50% |
| 2023-09-30 | -54.45% |
| 2023-06-30 | -46.20% |
| 2023-03-31 | -44.08% |
| 2022-12-31 | -40.99% |
| 2022-09-30 | -40.51% |
| 2022-06-30 | -38.35% |
| 2022-03-31 | -35.10% |
| 2021-12-31 | -30.96% |
| 2021-09-30 | -40.29% |
| 2021-06-30 | -39.60% |
| 2021-03-31 | -35.03% |
| 2020-12-31 | -27.63% |
| 2020-09-30 | -25.78% |
| 2020-06-30 | -9.98% |
| 2020-03-31 | -9.82% |
| 2019-12-31 | 15.91% |
| 2019-09-30 | 17.05% |
| 2019-06-30 | 6.42% |
| 2019-03-31 | 9.86% |
| 2018-12-31 | -28.89% |
| 2018-09-30 | -16.83% |
| 2018-06-30 | -29.33% |
| 2018-03-31 | -26.88% |
| 2017-12-31 | -22.59% |
| 2017-09-30 | -30.97% |
| 2017-06-30 | -28.82% |
| 2017-03-31 | -7.70% |
| 2016-12-31 | -5.16% |
| 2016-09-30 | -5.38% |
| 2016-06-30 | 23.62% |
| 2016-03-31 | 26.51% |
| 2015-12-31 | 29.93% |
| 2015-09-30 | 94.46% |
| 2015-06-30 | 68.99% |
| 2015-03-31 | 39.82% |
| 2014-12-31 | 42.58% |
